Canhao Wu, Qin Xu, Huiyuan Wang, Bin Tu, Jiaxin Zeng, Pengfei Zhao, Mingjie Shi, Hong Qiu, Yongzhuo Huang. Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” Acta Pharmaceutica Sinica B 12 (2022) 1523–1533J. Acta Pharmaceutica Sinica B, 2023, 13(11): 4664-4666. DOI: 10.1016/j.apsb.2023.08.007
|
Citation:
|
Canhao Wu, Qin Xu, Huiyuan Wang, Bin Tu, Jiaxin Zeng, Pengfei Zhao, Mingjie Shi, Hong Qiu, Yongzhuo Huang. Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” Acta Pharmaceutica Sinica B 12 (2022) 1523–1533J. Acta Pharmaceutica Sinica B, 2023, 13(11): 4664-4666. DOI: 10.1016/j.apsb.2023.08.007
|
Canhao Wu, Qin Xu, Huiyuan Wang, Bin Tu, Jiaxin Zeng, Pengfei Zhao, Mingjie Shi, Hong Qiu, Yongzhuo Huang. Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” Acta Pharmaceutica Sinica B 12 (2022) 1523–1533J. Acta Pharmaceutica Sinica B, 2023, 13(11): 4664-4666. DOI: 10.1016/j.apsb.2023.08.007
|
Citation:
|
Canhao Wu, Qin Xu, Huiyuan Wang, Bin Tu, Jiaxin Zeng, Pengfei Zhao, Mingjie Shi, Hong Qiu, Yongzhuo Huang. Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” Acta Pharmaceutica Sinica B 12 (2022) 1523–1533J. Acta Pharmaceutica Sinica B, 2023, 13(11): 4664-4666. DOI: 10.1016/j.apsb.2023.08.007
|
DownLoad: